Clinical data on CXA-101 to be presented at ICAAC (News-Medical-Net)

Calixa Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, will present pre-clinical and clinical data in 20 posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in San Francisco on September 12 to 15, 2009.
(read here…)

Related items

• Fargo researcher sees less toxic cancer treatment (Minnesota Public Radio)
• Biomoda applauds Senator for introducing legislative bill for lung cancer screening (News-Medical-Net)
• Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes (News-Medical-Net)
• Heat Treatment With Chemotherapy Kills Large Tumors; Approved By FDA; Next Stage Clinical Trials Start This Year At … (Medical News Today)
• Breakthrough Breast Cancer Therapy Reduces Mastectomies; Saves Breast (redOrbit)

Tags: Calixa, cancer, chemo, chemotherapy, clinical stage, company, development, Inc, interscience conference, nano, nanotech, nanotechnology, novel antibiotics, resistant infections, San Francisco, Technology, Therapeutics

This entry was posted on Monday, September 14th, 2009 at 2:23 pm and is filed under Technology.